Table 2. Correlations between the progression free survival (PFS) and Clinicopathological parameters.

Clinical parameters		Cases	Median PFS (Months)	Log-Rank χ2	P value
Gender	Male	270	34.40	0.073	0.787
	Female	189	31.87
Age(years)	≤60	260	33.53	0.098	0.754
	>60	199	32.00
BMI	≤25	237	58.63	0.034	0.854
	>25	84	49.03
Pathology grade	I-II	246	39.83	7.270	0.007
	III-IV	213	22.87
Tumor size	≤8cm	233	30.67	1.594	0.207
	>8cm	225	37.37
Lymph node	Negative	204	34.70	0.477	0.490
	Positive	252	28.37
TNM stage	I-II	190	40.40	11.382	0.001
	III-IV	269	23.53
EGFR expression level	Low	213	57.83	20.880	<0.001
	High	246	21.73
COX2 expression level	Low	73	28.37	0.250	0.617
	High	386	34.57
p53 expression level	Low	190	35.23	1.604	0.205
	High	268	30.53
nm23 expression level	Low	150	21.47	7.364	0.007
	High	308	37.77
EGFR & nm23 combined expression level	EGFR high & nm23 low	73	16.38	30.396	<0.001
	EGFR low & nm23 high	136	62.93

^*lack of partial data